SCOTUS PREVIEW: Myriad hinges on semantic strategies
This article was originally published in Scrip
Executive Summary
Arguing before the US Supreme Court is a game of semantics. And for Myriad Genetics, the outcome of the scrimmage it faces before the high court on 15 April on the viability of the firm's BRCA1 and BRCA2 gene patents weighs heavily on whether the courts muddles through the scientific language and concepts or gets it.